Ground effects on aircraft noise

A flight experiment was conducted to investigate air-to-ground propagation of sound near grazing incidence. A turbojet-powered aircraft was flown at low altitudes over the ends of two microphone arrays. An eight-microphone array was positioned along a 1850 m concrete runway. The second array consisted of 12 microphones positioned parallel to the runway over grass. Twenty-eight flights were flown at altitudes ranging from 10 m to 160 m. The acoustic data recorded in the field reduced to one-third-octave band spectra and time correlated with the flight and weather information. A small portion of the data was further reduced to values of ground attenuation as a function of frequency and incidence angle by two different methods. In both methods, the acoustic signals compared originated from identical sources. Attenuation results obtained by using the two methods were in general agreement. The measured ground attenuation was largest in the frequency range of 200 to 400 Hz. A strong dependence was found between ground attenuation and incidence angle with little attenuation measured for angles of incidence greater than 10 to 15 degrees

Assessment of ground effects on the propagation of aircraft noise: The T-38A flight experiment

A flight experiment was conducted to investigate air to ground propagation of sound at gazing angles of incidence. A turbojet powered airplane was flown at altitudes ranging from 10 to 160 m over a 20-microphone array positioned over grass and concrete. The dependence of ground effects on frequency, incidence angle, and slant range was determined using two analysis methods. In one method, a microphone close to the flight path is compared to down range microphones. In the other method, comparisons are made between two microphones which were equidistant from the flight path but positioned over the two surfaces. In both methods, source directivity angle was the criterion by which portions of the microphone signals were compared. The ground effects were largest in the frequency range of 200 to 400 Hz and were found to be dependent on incidence angle and slant range. Ground effects measured for angles of incidence greater than 10 deg to 15 deg were near zero. Measured attenuation increased with increasing slant range for slant ranges less than 750 m. Theoretical predictions were found to be in good agreement with the major details of the measured results

Rye Canyon X-ray noise test: One-third octave-band data

Acoustic data were obtained for the 25 ft. diameter X-wing rotor model during performance testing of the rotor system in hover. Data collected at the outdoor whirl tower test facility with a twelve microphone array were taken for approximately 150 test conditions comprised of various combinations of RPM, blade pressure ratio (BPR), and blade angle of attack (collective). The three test parameters had four values of RPM from 404 to 497, twelve values of BPR from 1.0 to 2.1, and six values of collective from 0.0 deg to 8.5 deg. Fifteen to twenty seconds of acoustic data were reduced to obtain an average 1/3 octave band spectrum for each microphone for each test condition. The complete, as measured, 1/3 octave band results for all the acoustic data are listed. Another part of the X-wing noise test was the acoustic calibration of the Rye Canyon whirl tower bowl. Corrections were computed which, when applied to as measured data, yield estimates of the free field X-wing noise. The free field estimates provide a more realistic measure of the rotor system noise levels. Trend analysis of the three test parameters on noise level were performed

Lateral Attenuation of High-By-Pass Ratio Engined Aircraft Noise

A flight experiment was conducted to investigate the lateral attenuation of high by pass ratio engined airplanes. A B-747 was flown at low altitudes over the ends of two microphone arrays. One array covering a lateral distance of 1600 m consisted of 14 microphones positioned over grass. The second array covered a lateral distance of 1200 m and consisted of 6 microphones positioned over a concrete runway. Sixteen runs were flown at altitudes ranging from 30 to 960 m. The acoustic information recorded in the field was reduced to one third octave band spectral time histories and synchronized with tracking and weather information. Lateral attenuation as a function of elevation angle was calculated in overall, A-weighted, tone-corrected perceived noise level, and effective perceived noise level units. The B-747 results are compared with similar results for a turbojet-powered T-38 airplane and the SAE recommended lateral attenuation prediction procedure. Less lateral attenuation was measured for the B-747 than for the T-38. The B-747 lateral attenuation values also fell below the SAE curve

SEA analysis in the cabin of a regional turboprop with metamaterial lining panels

The main goal of this paper is to evaluate the comfort, and hence the interior sound pressure levels, in the cabin of a regional turboprop with metamaterial lining panels under Turbulent Boundary Layer flow over the fuselage during cruise flight conditions. In the preliminary work phase, the design of metamaterial and a numerical analysis at component level were performed. Then, the CAD model of the fuselage was created representing the typical features and dimensions of an airplane for regional flights and a Statistical Energy Analysis (SEA) model was built by using Va One software. An investigation on the influence of designed metamaterial on the soundproofing of the cabin was presented. Results reveal a reduction in Sound Pressure Level (SPL) of almost 5 dB with respect to classical materials, in overall the frequency range and for all the cavities analyzed, in the configuration with metamaterial applied as core of the sandwich lining panels

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

High Frequency, Low Background Rate Extrapleural Programmed Intermittent Bolus Ropivacaine Provides Superior Analgesia Compared with Continuous Infusion for Acute Pain Management Following Thoracic Surgery: A Retrospective Cohort Study.

Background: Thoracic surgery often results in severe postoperative pain. Regional analgesia via surgically placed extrapleural local anaesthetic (LA) and continuous infusion (CI) is an effective technique, however usually requires supplemental opioid to achieve satisfactory patient analgesia. We hypothesized that high frequency, low background rate extrapleural programmed intermittent boluses (PIB) of LA by could achieve superior patient analgesia and reduced oral morphine equivalent daily dosage (OMEDD) requirements for up to 3 days after thoracic surgery vs. CI. Methods: We retrospectively analysed data from 84 adult patients receiving extrapleural analgesia after thoracic surgery in a single tertiary teaching hospital. The primary outcome measure was the effect of PIB vs. CI on maximum daily 11-point numerical rating scale (NRS-11) ratings as determined by multivariate linear regression analysis, corrected for OMEDD use, total daily LA dose, surgery type, age, opioid type, and use of ketamine analgesia. Secondary outcome measures were the effect on OMEDD use, the effect of total 'rescue' LA boluses, and univariate analyses of the above outcomes and variables. Results: PIB on day 0, and a higher proportion of LA given as rescue boluses on day 1 were associated with reduced maximum NRS-11 ratings [standardized/ [unstandardized] beta coefficient -0.34/ [-0.92 NRS-11 if PIB] (P = 0.007); and -0.26/ [-0.029 NRS-11 per mg/kg extrapleural ropivacaine] (P = 0.03)], respectively. Only patient age was associated with reduced OMEDD use [day 0: -0.58/ [-4.4 OMEDDs per year of age] (P ≤ 0.005); day 1: -0.49/ [-3.56 OMEDDs per year of age] (P ≤ 0.005); day 2: -0.32/ [-1.9 OMEDDs per year of age] (P = 0.04)]. OMEDD use on day 2, however, was associated with slightly higher maximum NRS-11 ratings [+0.28/ +0.006 NRS-11 per mg OMEDD (P = 0.036)]. On univariate analysis, PIB patients achieved the largest difference in OMEDD use [-98 mg (95% CI -73 to -123 mg)] and NRS-11 ratings [-1.1 (-0.4 to -1.8)] against CI patients on day 3. Conclusions: Use of high frequency, low background rate PIB extrapleural LA after thoracic surgery appears to have a modest beneficial effect on acute pain, but not OMEDD use, over CI when adjusted for patient, surgical and other analgesic factors after thoracic surgery. Further work is required to elucidate the potential magnitude of effect that extrapleural LA given by PIB over CI can achieve